Financial Ratios

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE1317.3057.35 (+4.55 %)
PREV CLOSE ( ) 1259.95
OPEN PRICE ( ) 1289.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10903
TODAY'S LOW / HIGH ( )1259.45 1332.55
52 WK LOW / HIGH ( )575 1617.8
NSE1315.3552.25 (+4.14 %)
PREV CLOSE( ) 1263.10
OPEN PRICE ( ) 1274.00
BID PRICE (QTY) 1315.35 (42)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 276479
TODAY'S LOW / HIGH( ) 1257.15 1329.95
52 WK LOW / HIGH ( )575 1619.05
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)30.8624.7920.6526.1319.59
   CEPS(Rs)34.2428.1823.6228.7322.35
   DPS(Rs)4.504.003.002.502.20
   Book NAV/Share(Rs)148.16120.7498.3378.0656.22
   Tax Rate(%)20.0924.9525.5821.9226.89
Margin Ratios
   Core EBITDA Margin(%)41.5041.5643.4139.2235.13
   EBIT Margin(%)55.4847.4243.5347.9937.84
   Pre Tax Margin(%)55.4647.4043.4947.9637.74
   PAT Margin (%)44.3235.5832.3737.4427.60
   Cash Profit Margin (%)49.1740.4637.0241.1731.48
Performance Ratios
   ROA(%)19.8719.6220.1332.1231.19
   ROE(%)22.9722.6523.4238.9241.30
   ROCE(%)28.3329.6430.9249.0555.76
   Asset Turnover(x)0.450.550.620.861.13
   Sales/Fixed Asset(x)1.911.971.952.592.61
   Working Capital/Sales(x)1.021.041.111.672.61
Efficiency Ratios
   Fixed Capital/Sales(x)0.520.510.510.390.38
   Receivable days49.0152.60120.02119.0771.97
   Inventory Days32.5723.3917.8615.8717.67
   Payable days134.94120.50113.8384.99101.94
Valuation Parameters
   PER(x)19.3327.4319.5710.8120.54
   PCE(x)17.4324.1217.119.8318.00
   Price/Book(x)4.035.634.113.627.16
   Yield(%)0.750.590.740.890.55
   EV/Net Sales(x)8.059.165.623.945.59
   EV/Core EBITDA(x)13.3517.5211.667.6113.39
   EV/EBIT(x)14.5219.3212.918.2014.76
   EV/CE(x)3.274.593.153.015.56
   M Cap / Sales8.579.766.334.055.67
Growth Ratio
   Net Sales Growth(%)0.109.40-8.55-1.6925.86
   Core EBITDA Growth(%)15.4818.76-14.8121.8635.30
   EBIT Growth(%)17.1219.18-17.0524.6938.60
   PAT Growth(%)24.6920.25-20.9533.3944.82
   EPS Growth(%)24.5320.01-20.9633.3744.77
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)4.526.136.635.933.49
   Quick Ratio(x)4.175.696.315.583.20
   Interest Cover(x)2443.922782.221235.941369.24404.61
   Total Debt/Mcap(x)0.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.